A Study to Investigate the Safety, Tolerability and Pharmacokinetics of ABY-035

Summary

The purpose of this first-in-human study is to investigate the safety and tolerability of ABY-035 when administered intravenously and subcutaneously, to healthy volunteers and to psoriasis patients.

Timeline

Start

2016-02

Primary completion

2018-01-10

Completion

2018-01-10

Publications

• Klint S, Feldwisch J, Gudmundsdotter L, Dillner Bergstedt K, Gunneriusson E, Hoiden Guthenberg I, Wennborg A, Nyborg AC, Kamboj AP, Peloso PM, Bejker D, Frejd FY. Izokibep: Preclinical development and first-in-human study of a novel IL-17A neutralizing Affibody molecule in patients with plaque psoriasis. MAbs. 2023 Jan-Dec;15(1):2209920. doi: 10.1080/19420862.2023.2209920.

Drugs

Indications